For several months, Orthopus has been preparing a clinical trial for our set of upper-limb mechanical prostheses . Thanks to... View Article
Author Archives for Adeline Chauvigné
Nantes > Kathmandu: a clinical trial for ORTHOPUS mechanical prostheses
4 November 2025For several months, Orthopus has been preparing a clinical trial for our set of upper-limb mechanical prostheses . Thanks to... View Article
Responsible innovation should supersede the precautionary approach
Interview with Franck Zal, the founder of Hemarina, Vice-president of Atlanpole Biotherapies President of a biotech firm that develops “oxygen... View Article
Responsible innovation should supersede the precautionary approach
4 November 2025Interview with Franck Zal, the founder of Hemarina, Vice-president of Atlanpole Biotherapies President of a biotech firm that develops “oxygen... View Article
New member | Amossys
Audit, consulting, evaluation of security products, training, incident response, R&D… In order to help our customer secure their digital environment,... View Article
New member | Amossys
4 November 2025Audit, consulting, evaluation of security products, training, incident response, R&D… In order to help our customer secure their digital environment,... View Article
New member | NeuroKyma
PROVIDER OF ADVANCED TECHNOLOGY FOR PREDICTIVE ANALYSIS ON CNS TRIALS DISEASES AT THE CROSSING OF E-HEALTH AND NEURO-IMAGING Our mission is... View Article
New member | NeuroKyma
4 November 2025PROVIDER OF ADVANCED TECHNOLOGY FOR PREDICTIVE ANALYSIS ON CNS TRIALS DISEASES AT THE CROSSING OF E-HEALTH AND NEURO-IMAGING Our mission is... View Article
XENOTHERA signs a pre-order contract of its anti-COVID treatment with the French government
XENOTHERA announces the signature of a contract to reserve 30,000 unit doses of XAV-19 with the French Ministry of Health... View Article
XENOTHERA signs a pre-order contract of its anti-COVID treatment with the French government
4 November 2025XENOTHERA announces the signature of a contract to reserve 30,000 unit doses of XAV-19 with the French Ministry of Health... View Article
GlioCure expands its know-how and technological offer to nanovectors
GlioCure SA, a biotechnology company specializing in neuro-oncology, announces the launch of Cure’nCaps Solutions (www.curencaps.com), a platfom for the formulation... View Article
GlioCure expands its know-how and technological offer to nanovectors
4 November 2025GlioCure SA, a biotechnology company specializing in neuro-oncology, announces the launch of Cure’nCaps Solutions (www.curencaps.com), a platfom for the formulation... View Article
OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine
First-in-human study evaluating CoVepiT, a multi-variant T cell COVID-19 vaccine for people at risk and vulnerable populations. CoVepiT is a... View Article
OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine
4 November 2025First-in-human study evaluating CoVepiT, a multi-variant T cell COVID-19 vaccine for people at risk and vulnerable populations. CoVepiT is a... View Article
Valneva to Participate in the World’s First COVID-19 Vaccine Booster Trial in the UK
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article
Valneva to Participate in the World’s First COVID-19 Vaccine Booster Trial in the UK
4 November 2025Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article
New member | Attonuclei
ATTONUCLEI took advantage of its 10 years of experience in functionalized Quantum Dots our company is a high-tech company whose... View Article
New member | Attonuclei
4 November 2025ATTONUCLEI took advantage of its 10 years of experience in functionalized Quantum Dots our company is a high-tech company whose... View Article
OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance, to Finance Further Development of CoVepiT, its Multi-Target and Multi-Variant COVID-19 Vaccine in Phase 1 Clinical Phase
CoVepiT is a SARS-CoV-2 vaccine activating T cell defences through CD8 T cell multiepitopes. CoVepiT epitopes* are selected from 11... View Article
OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance, to Finance Further Development of CoVepiT, its Multi-Target and Multi-Variant COVID-19 Vaccine in Phase 1 Clinical Phase
4 November 2025CoVepiT is a SARS-CoV-2 vaccine activating T cell defences through CD8 T cell multiepitopes. CoVepiT epitopes* are selected from 11... View Article